Ohio's Third Frontier Commission has voted to award Neoprobe a grant of $1 million to fund ongoing development of Neoprobe's Lymphoseek radiopharmaceutical initiative, subject to State Controlling Board review.
The Ohio Third Frontier grant will be used to accelerate clinical testing for Neoprobe's Phase 3 trial in patients diagnosed with head and neck squamous cell carcinoma, according to the Dublin, Ohio-based company. The trial is intended to expand the proposed product labeling for Lymphoseek. Neoprobe was among eight companies awarded Medical Imaging Program grants by the commission.
The Lymphoseek initiative involves a collaboration of several Ohio-based companies as well as cancer centers in the U.S. and Europe. Neoprobe said its collaborators on this grant included Cardinal Health in Dublin, Ohio; Phylogeny in Columbus, Ohio; StatKing Consulting in Fairfield, Ohio; and Integrated Bioscience Solutions in Loveland, Ohio.